Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care.
The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75.
This year, the newly closed acquisition of Firefly Bio and the partnership with Sail Biomedicines are forecast to cut adjusted earnings by 64 cents a share.
Sounds like a typical warning about the price of the deal.
No, it is not.
The two mergers could trim 2027 adjusted earnings by $1.36 a share, Johnson & Johnson said, more than twice the expected damage this year. Almost half of that potential damage, or $1.28 per share, comes from Sail and assumes Johnson & Johnson executes its exclusive acquisition option.
This gives you an upside-down earnings signal.
If the biotech’s experimental medicines continue to advance and management becomes more convinced of their commercial potential, Johnson & Johnson would likely be more willing to invest billions to buy Sail. This means incentivizing scientific research could lead to more payouts and a higher near-term earnings hit.
The revenue guidance remains $100.8 billion to $101.4 billion, so the drop to guidance is not because of a sudden deterioration in the performance of Johnson & Johnson’s current businesses. Shares dropped 1.6% in after-hours trade after the announcement.
The subtext is troubling: Some of the worst financial news could signal that Johnson & Johnson’s largest biotech venture is paying off.
“Sail’s innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way,” Johnson & Johnson research and development chief John Reed said.
Johnson & Johnson created an upside-down earnings trap
The Sail deals include an initial payment of $785 million from Johnson & Johnson, which includes an equity investment of $465 million. Sail might earn another $140 million if it meets certain development goals, while Johnson & Johnson has an exclusive option to buy the rest of the company for $2.58 billion.
The acquisition will hurt 2026 adjusted earnings by around 18 cents a share. Should Johnson & Johnson execute the acquisition option, dilution would jump to about $1.28 a share in 2027, the forecast said.
That structure breaks the normal picture of a decline in earnings.
If the trial program is a failure, Johnson & Johnson might decide not to exercise its option to buy, which would curb future spending but also eliminate much of the strategic rationale behind the deal.
Related: Johnson & Johnson bets $1 billion on hard-to-treat cancer
Strong data, successful milestones, or more confidence in Sail might push Johnson & Johnson toward the multibillion-dollar purchase, causing a considerably higher reported earnings burden.
So the $1.28 a share impact isn’t just a projected expense. It is also a possible price for conviction.
Sail is developing in vivo chimeric antigen receptor T-cell, or CAR-T, therapy. Traditional CAR-T therapies usually involve taking immune cells from a patient, modifying them outside of the body, and putting them back. Instead, Sail’s platform reprograms particular immune cells inside the patient.
Johnson & Johnson and Sail will at first concentrate on immune-mediated disorders. They’re aiming to reboot broken immune systems and potentially provide long-lasting disease control through a therapy that could be easier and more scalable than cell therapy.
The medicinal possibility is tremendous, yet the science is still exploratory.
Johnson & Johnson is paying for access, equity, and acquisition rights well before Sail has a drug authorized or generating considerable commercial revenue. As the technology progresses, the corporation could spend billions, only to hit clinical or regulatory or manufacturing snags down the road.
For investors, that means a painful sequence: costs first, scientific confirmation later, and sales perhaps years off.
Sail could make Johnson & Johnson’s good news look terrible
The Sail agreement explains why investors cannot judge Johnson & Johnson’s 2027 performance by just using the earnings number.
If Sail hits its development milestones and is bought out by Johnson & Johnson for $2.58 billion. Reported adjusted profitability could decrease even more steeply, but management would also be communicating that it sees enough scientific and strategic value to devote substantially more cash.
The contrary could make for a cleaner-looking income statement.
If the technology doesn’t prove out and Johnson & Johnson decides not to buy Sail, the corporation might escape much of the anticipated 2027 dilution. Earnings would be stronger, but one of its most ambitious potential growth platforms would have lost some traction.
This doesn’t mean lower earnings are inevitably optimistic.
More Healthcare/Health:
- Medicare’s new $50 GLP-1 deal has a catch most overlook
- Mark Cuban warns AI could make US healthcare even worse
- GLP-1 weight-loss drug popularity reaches new heights with Americans
But more expenditure can damage shareholder value if management overestimates the prospects of a technology or overpays for risky assets. Ultimately the Sail platform must deliver successful trials, regulatory clearances, and economically viable therapies before investors can decide whether the investment was worthwhile.
The cost trend of Firefly Bio is different:
In June, Johnson & Johnson said it would buy the cancer-technology firm for $1 billion in cash. Firefly’s platform employs antibodies to ferry protein-degrading medicines into cancer cells, starting with KRAS-driven malignancies that have historically proven hard to treat.
The deal will increase the anticipated impact on Johnson & Johnson’s adjusted earnings by 46 cents in 2026 but only eight cents in 2027. Sail has a lower impact to start, then becomes the primary earnings concern next year.
Together, the transactions are illustrative of the company’s strategy: endure the short-term financial pain to acquire technology that could potentially build new oncology and immunology businesses down the road.
Johnson & Johnson is turning earnings into a science scoreboard
The updated guidance from Johnson & Johnson does not mean that its existing drug and medical-device businesses ceased growing overnight.
Two weeks before the transaction update, the business said it posted second-quarter sales of $25.31 billion, up nearly 7%, and adjusted earnings of $2.90 a share, beating analysts’ forecasts. Its Innovative Medicine unit reported quarterly sales of $16.38 billion.
Management is using that financial muscle to buy tomorrow’s pipeline before tomorrow’s products are available.
That could be a sensible thing to do for a big pharmaceutical corporation. It takes years to develop medications in-house; there are lots of failures, and exciting biotechnology platforms can become a lot more expensive once they have good human-trial results.
Buying early leaves more upside.
It intensifies ambiguity as well.
Johnson & Johnson has put down $1 billion for Firefly’s preclinical cancer platform and may spend billions more on Sail’s in vivo CAR-T technology. Firefly’s own announcement of its acquisition emphasized that clinical research, regulatory approval, and commercial success are all uncertain.
The result is a forecast investors have to interpret backward.
A bigger 2027 profit hit may indicate Johnson & Johnson thought Sail’s program was worth buying. A lesser hit could suggest management avoided a costly purchase or that the scientific potential didn’t warrant one.
Key takeaways for Johnson & Johnson investors
- 2026 adjusted earnings guidance fell to $10.96 to $11.11 a share.
- Firefly and Sail will reduce 2026 earnings by 64 cents a share.
- The potential 2027 impact rises to $1.36 a share.
- Sail accounts for $1.28 of the projected 2027 reduction.
- Johnson & Johnson must pay $2.58 billion to exercise its Sail acquisition option.
- Revenue guidance remains unchanged at $100.8 billion to $101.4 billion.
- A bigger earnings hit may accompany scientific progress, but it would not guarantee eventual commercial success.
Johnson & Johnson isn’t just acquiring two biotech properties.
This has produced a financial conundrum where success, expenditure, and earnings pressure could converge.
The bull case is that the corporation is buying potentially transformational cancer and autoimmune tech before anyone realizes what it’s worth. Should either platform develop major drugs, present cutbacks in earnings could look trivial compared to the potential revenue possibility.
The bear case is that Johnson & Johnson is spending billions on appealing theories that may never translate into approved products.
In any case, the headline earnings figure will no longer represent the whole story.
If its newest biotechnology development were moving forward or if management thought it was not worth buying, Johnson & Johnson may post lower adjusted earnings in 2027.
The most dangerous mistake investors can make is to celebrate the prettier figure before finding out what’s behind it.
Related: Morgan Stanley has a bold message for Johnson & Johnson
